Needham Reiterates Buy on Biogen (NASDAQ:BIIB) , Maintains $325 Price Target

By / / Biogen, Needham

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $325 price target.

Scroll to Top